Alzinova AB is a Sweden-based company, which is primarily involved in the biotechnology industry. The Company is engaged in the discovery and development of therapeutics for the treatment of Alzheimerâ€™s disease. The Company focuses on development of a specific oligomer-directed vaccine (ALZ-101), as well as on the development of diagnostics based on a monoclonal antibody (ALZ-201). Both products are specifically directed towards the form of oligomeric AÎ² that damages brain synapses.

Employees

Sector

Biotechnology & Medical Research

Calendar

12/11 Earnings release - Q3 2026

More about the company

Quotes

Date	Price	Change	Volume
29/26/29	SEK 0.3755	+1.08%	41,33,745
28/26/28	SEK 0.3715	-3.88%	25,67,496
27/26/27	SEK 0.3865	-7.20%	41,30,881
26/26/26	SEK 0.4165	-1.65%	11,19,099
23/26/23	SEK 0.4235	-0.47%	5,47,781

Delayed Quote Nasdaq Stockholm

More quotes

EPS Estimates

Evolution of Analysts' Estimates - EPS - Alzinova AB

Revisions to estimates

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Alzinova AB

Company calendar

Market Closed - Nasdaq Stockholm 10:30:00 29/10/2026 pm IST			5-day change	1st Jan Change
0.3755 ^SEK	+1.08%		-11.75%	-54.70%

21/10	Alzinova Finalizes US Trial Sites for Mid-stage Alzheimer's Disease Vaccine Study	MT
21/10	Alzinova selects seven U.S. trial sites ahead of phase IIa study	FW

Market Cap	12Cr 1.19Cr 1.07Cr 98.42L 89.06L 1.67Cr 113.42Cr 1.69Cr 4.68Cr 59Cr 4.47Cr 4.37Cr 188Cr	P/E 2026 *	-2.65x	P/E 2027 *	-1.38x
Enterprise Value	11Cr 1.1Cr 98.5L 90.87L 82.23L 1.54Cr 104.72Cr 1.56Cr 4.33Cr 55Cr 4.13Cr 4.04Cr 173.59Cr	EV / Sales 2026 *	3.46x	EV / Sales 2027 *	-
Free-Float	82.68%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Nasdaq Stockholm	ALZ	Delayed
Deutsche Boerse AG	78D	Delayed
Börse Stuttgart	78D	Delayed
CBOE		Real-time
CBOE		Real-time

21/10	Alzinova Finalizes US Trial Sites for Mid-stage Alzheimer's Disease Vaccine Study	MT
21/10	Alzinova selects seven U.S. trial sites ahead of phase IIa study	FW
21/10	Alzinova AB Finalises Selection Of Seven US Clinical Sites As ADVANCE Phase 2a Study Moves Toward First Participant Enrolment	CI
20/10	Alzinova carries out directed issue worth SEK 3.6m to Mangold	FW
15/10	Calendar Thursday October 15	FW
08/10	Alzinova AB Presents Latest Developments In ALZ-101 And Blood-Based Diagnostics At Redeye Neurology Day	CI
08/10	Redeye reiterates fair value of SEK 0.90 for Alzinova following rights issue	FW
08/10	Alzinova's rights issue subscribed to 86.2 percent, raises SEK 44m	FW
07/10	RX Securities reiterates Buy on Alzinova, cuts fair value to SEK 2.50	FW
07/10	Alzinova Announces Preliminary Outcome Of The Rights Issue	RE
07/10	Alzinova's rights issue subscribed to just over 80 percent	FW
02/10	Alzinova Broadens Shareholder Base With New Investor	RE
02/10	Alzinova's main shareholder sells shares for SEK6.5m, subscribes to its pro rata portion of the offering	FW

Alzinova AB Share Price

Stocks

ALZ

SE0007413455

Biotechnology & Medical Research

Valuation: Alzinova AB

Chart: Alzinova AB

Latest news: Alzinova AB

Analysts' recommendations: Alzinova AB

Press Releases: Alzinova AB

Quotes and Performance

Price Extremes

Managers and Directors: Alzinova AB

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

08/10	Alzinova: Rights issue subscribed to 86.2%	AQ
08/10	Alzinova to present latest developments in ALZ-101 and blood-based diagnostics at Redeye Neurology Day	AQ
08/10	Alzinova: Rights issue completed	AQ
07/10	Alzinova announces final outcome of the rights issue	AQ
06/10	Alzinova announces preliminary outcome of the rights issue	AQ

1 day	+1.08%
1 week	-11.75%
Current month	-10.38%
1 month	-9.30%
3 months	-61.61%
6 months	-16.56%
Current year	-54.70%

1 week	0.34	0.43
1 month	0.34	0.49
Current year	0.34	1.61
1 year	0.34	2.07
3 years	0.34	4.62
5 years	0.34	7.74
10 years	0.34	44.9

Manager	Title	Age	Since
Tord Labuda CEO	Chief Executive Officer	59	01/10/2024
Anders Sandberg COO	Chief Operating Officer	54	17/08/2011
Erik Kullgren DFI	Director of Finance/CFO	57	27/03/2024

Director	Title	Age	Since
Clas Malmeström BRD	Director/Board Member	61	01/09/2015
Anders Waas BRD	Director/Board Member	69	01/01/2018
Carol Routledge BRD	Director/Board Member	65	01/01/2018

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ALZINOVA AB	+1.08%	-11.75%	-75.49%	-84.80%	1.18Cr
WUXI APPTEC CO., LTD.	+0.34%	-3.03%	+37.45%	+61.06%	6.41TCr
ARGENX SE	+0.98%	+2.68%	+12.25%	+83.90%	5.55TCr
LONZA GROUP AG	+1.75%	+2.01%	+13.30%	+105.71%	5.3TCr
IQVIA HOLDINGS INC.	-1.43%	-1.17%	+26.27%	+55.26%	4.6TCr
BEONE MEDICINES AG	-0.48%	-2.80%	+18.01%	+99.11%	4.25TCr
REVOLUTION MEDICINES, INC.	+0.82%	+1.37%	+227.94%	+936.89%	4.04TCr
CELLTRION, INC.	-0.26%	-4.20%	+10.86%	+45.18%	3.23TCr
GENMAB A/S	-2.07%	+42.73%	+103.77%	+90.26%	3.45TCr
WUXI BIOLOGICS (CAYMAN) INC.	-2.72%	-8.79%	+22.58%	-5.63%	2.42TCr
Average	-0.23%	+2.31%	+39.69%	+138.70%	3.93TCr
Weighted average by Cap.	-0.11%	+3.13%	+49.56%	+161.15%

	2026 *	2027 *
Net sales	3.14Cr 31.8L 28.48L 26.28L 23.78L 44.47L 30Cr 45.18L 1.25Cr 16Cr 1.19Cr 1.17Cr 50Cr	-
Net income	15.5L 2L 1L 1L 1L 2L 1.5Cr 2L 6L 78.36L 6L 6L 2.48Cr	-8.4Cr -85.2L -76.32L -70.41L -63.71L -1.19Cr -81Cr -1.21Cr -3.35Cr -42Cr -3.2Cr -3.13Cr -134.49Cr
Net Debt	-90L -9L -8L -8L -7L -12.77L -8.69Cr -12.97L -35.9L -4.55Cr -34.26L -33.53L -14Cr	-40L -4L -4L -3L -3L -6L -3.86Cr -6L -15.96L -2.02Cr -15.23L -14.9L -6.4Cr